which glp-1 drugs are approved for obesity What to Make of the Coverage and Cost Landscape GLP-1 drug coverage for obesity

Liraglutide and exenatide are already off-patent and semaglutide will begin losing exclusivity in several large countries from 2026 (read more in our blog Off-patent semaglutide in 2026)

But this does not substitute for controlled trials, and patients should understand they are, in effect, early adopters of an approach that is not yet evidence-based in the traditional sense

Some further limitations of the present metaanalysis should be considered for a correct interpretation of its results

Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial

GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents

Smooth process, good experience